Page last updated: 2024-12-07

n-allyladenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

N-Allyladenosine (N-Ade) is a nucleoside analog that exhibits a wide range of pharmacological activities. It has been shown to possess anti-inflammatory, analgesic, and neuroprotective properties. N-Ade is synthesized by the allylation of adenosine, a naturally occurring nucleoside. The compound has been shown to inhibit the activity of various enzymes, including adenosine deaminase and phosphodiesterase. This inhibition leads to an increase in adenosine levels, which is known to have beneficial effects on various physiological processes. N-Ade is a promising candidate for the development of new therapeutic agents for various diseases. It is currently being investigated for its potential use in the treatment of inflammatory diseases, pain, and neurodegenerative disorders. Further research is needed to fully understand its mechanisms of action and potential clinical applications.'

Cross-References

ID SourceID
PubMed CID97078
CHEMBL ID1290749
CHEBI ID165838
SCHEMBL ID6761791
MeSH IDM0200548

Synonyms (13)

Synonym
n-allyladenosine
15763-12-9
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(prop-2-enylamino)purin-9-yl]oxolane-3,4-diol
CHEBI:165838
CHEMBL1290749
n6-allyladenosine
nsc 98777
adenosine, n-2-propenyl-
SCHEMBL6761791
(2r,3r,4s,5r)-2-[6-(allylamino)purin-9-yl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
n-2-propenyl-adenosine
AKOS040753192
adenosine, n-2-propen-1-yl-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
purine nucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID90274Concentration required for 50% growth inhibition of the following cell lines human burkitt lymphoma cells1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID539777Cytotoxicity against human J82 cells at 10 uM after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
N⁶-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.
AID130975Antitumor activity against mouse leukemia, L-1210(DBA/2 Ha Mice) % increase in life span at 3.12 mg/kg of dose per day1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID539783Induction of MMP9 activity in human T24 cells after 1 hr by zymography2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
N⁶-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.
AID138630Antitumor activity against mouse leukemia, L-1210(DBA/2 Ha Mice) mean life span (days) of the mouse after fractionated dosage(dose divided in two halves and administered in two daily injections) at 6.25 mg/kg of dose per day1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID539779Cytotoxicity against human MDA-MB-231 cells at 10 uM after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
N⁶-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.
AID138966Antitumor activity against slow growing spontaneous mammary tumors in the DBA/2 Ha-DD mouse number of days reacquired fro tumor growth 3.8 mg/kg/day x 5 melphalan once in 5 days1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID539778Cytotoxicity against human Caco-2 cells at 10 uM after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
N⁶-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.
AID138631Antitumor activity against slow growing spontaneous mammary tumors in the DBA/2 Ha-DD mouse mean life span in days at 50 mg/kg give 5 times once in 5 days1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID139992Concentration required for 50% growth inhibition of the following cell lines mouse fibro blasts1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID155531Inhibition of Trypanosoma brucei phosphoglycerate kinase (PGK); inactive at 4 mM2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Adenosine analogues as inhibitors of Trypanosoma brucei phosphoglycerate kinase: elucidation of a novel binding mode for a 2-amino-N(6)-substituted adenosine.
AID539782Inhibition of human T24 cells invasion on Matrigel after 24 hrs2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
N⁶-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.
AID539776Cytotoxicity against human T24 cells at 10 uM after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
N⁶-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.
AID130490antitumor activity against mouse leukemia, L-1210(DBA/2 Ha Mice) % increase in life span at 3.12 mg/kg of dose per day1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID539781Growth inhibition of human T24 cells assessed as reduction of cell count after trypsinization at 10 uM after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
N⁶-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.
AID130977Antitumor activity against slow growing spontaneous mammary tumors in the DBA/2 Ha-DD mouse % increased in life span 3.8 mg/kg/day x 5 melphalan + 50 mg/kg/day compound1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID103053Concentration required for 50% growth inhibition of human breast tumor cells MCF-7 human breast carcinoma cells1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID25507HPLC capacity factor (k')1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID539780Cytotoxicity against human T24 cells assessed as inhibition of clones formation at 10 uM after 1 week by clonogenic assay2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
N⁶-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.
AID91137Concentration required for 50% growth inhibition of the following cell lines human fibro blast cells1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID201887Concentration required for 50% growth inhibition of the following cell lines sarcoma S-180 cells1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID130976Antitumor activity against slow growing spontaneous mammary tumors in the DBA/2 Ha-DD mouse % increased in life span 3.8 mg/kg/day x 5 melphalan + 50 mg/kg/day1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID539784Inhibition of human T24 cell migration by wound healing assay2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
N⁶-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity.
AID48652Concentration required for 50% growth inhibition of the following cell lines Carcinoma TA-3 cells1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID138629Antitumor activity against mouse leukemia, L-1210(DBA/2 Ha Mice) mean life span ( days) of the mouse after the dosage at 1.56 mg/kg of dose per day1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID228918Molar potency ratio was evaluated1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID201700Concentration required for 50% growth inhibition of human breast tumor cells SW-613 human breast adenocarcinoma cells1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID1646835Activation of human STING expressed in monocytes co-expressing IFN assessed as alkaline phosphatase secretion by SEAP reporter gene assay2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Structure activity relationship, 6-modified purine riboside analogues to activate hSTING, stimulator of interferon genes.
AID101497Concentration required for 50% growth inhibition of the following cell lines Leukemia L-1210 cells1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
AID89994Concentration required for 50% growth inhibition of the following cell lines human bladder carcinoma cells1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Some short-chain N6-substituted adenosine analogues with antitumor properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's1 (16.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.47 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]